Literature DB >> 29746136

Relative Activity Factor (RAF)-Based Scaling of Uptake Clearance Mediated by Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 in Human Hepatocytes.

Saki Izumi1, Yoshitane Nozaki1, Hiroyuki Kusuhara2, Koichiro Hotta1, Toshiki Mochizuki1, Takafumi Komori1, Kazuya Maeda2, Yuichi Sugiyama3.   

Abstract

In vitro-in vivo extrapolation based on uptake clearance determined in human hepatocytes has been used to predict in vivo hepatic clearance of organic anion transporting polypeptide (OATP) substrates. This study evaluated the relative activity factor (RAF) approach to extrapolate active uptake clearance in transporter-transfected cell systems (CLuptake) to that in human hepatocyte suspensions (PSinf,act). RAF values for OATP1B1 and OATP1B3 were determined in two batches of cryopreserved human hepatocytes using estrone-3-sulfate and cholecystokinin octapeptide as reference substrates, respectively. Fourteen OATP1B substrate drugs selected (atorvastatin, bosentan, cerivastatin, fexofenadine, fluvastatin, glibenclamide, irbesartan, nateglinide, pitavastatin, pravastatin, rosuvastatin, telmisartan, torasemide, and valsartan) showed temperature-dependent uptake in human hepatocytes. In transporter-transfected cells, OATP1B1- and OATP1B3-mediated uptake was observed in all compounds except for telmisartan. RAF-based net CLuptake was mainly accounted for by OATP1B1 (72.3-99.7%) and fell within the 3-fold of PSinf,act observed in human hepatocytes in 11 out of 13 compounds (excluding telmisartan). This study demonstrated that the RAF approach provides a quantitative index of OATP1B1- and OATP1B3-mediated PSinf,act in human hepatocytes, which will facilitate the optimization of the pharmacokinetic properties of OATP1B substrates at nonclinical stages of drug development.

Entities:  

Keywords:  hepatic uptake; human hepatocytes; organic anion transporting polypeptide (OATP); relative activity factor (RAF)

Mesh:

Substances:

Year:  2018        PMID: 29746136     DOI: 10.1021/acs.molpharmaceut.8b00138

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  6 in total

1.  Role of Uptake Transporters OAT4, OATP2A1, and OATP1A2 in Human Placental Bio-disposition of Pravastatin.

Authors:  Valentina M Fokina; Svetlana Patrikeeva; Xiao-Ming Wang; Saki Noguchi; Masatoshi Tomi; Jörg König; Mahmoud S Ahmed; Tatiana Nanovskaya
Journal:  J Pharm Sci       Date:  2021-09-28       Impact factor: 3.534

Review 2.  Multi-factorial pharmacokinetic interactions: unraveling complexities in precision drug therapy.

Authors:  Baron Bechtold; John Clarke
Journal:  Expert Opin Drug Metab Toxicol       Date:  2021-01-20       Impact factor: 4.481

3.  Vitamin D Deficiency Impacts Exposure and Response of Pravastatin in Male Rats by Altering Hepatic OATPs.

Authors:  Jinfu Peng; Guoping Yang; Zhijun Huang
Journal:  Front Pharmacol       Date:  2022-02-17       Impact factor: 5.810

4.  Solute Carrier Transportome in Chemotherapy-Induced Adverse Drug Reactions.

Authors:  Jason T Anderson; Kevin M Huang; Maryam B Lustberg; Alex Sparreboom; Shuiying Hu
Journal:  Rev Physiol Biochem Pharmacol       Date:  2022       Impact factor: 7.500

5.  Novel testing strategy for prediction of rat biliary excretion of intravenously administered estradiol-17β glucuronide.

Authors:  Annelies Noorlander; Eric Fabian; Bennard van Ravenzwaay; Ivonne M C M Rietjens
Journal:  Arch Toxicol       Date:  2020-11-07       Impact factor: 5.153

Review 6.  Examination of Physiologically-Based Pharmacokinetic Models of Rosuvastatin.

Authors:  Christine M Bowman; Fang Ma; Jialin Mao; Yuan Chen
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-12-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.